ExodusPoint Capital Management’s Emergent Biosolutions EBS Stock Holding History

ExodusPoint Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19,347	Closed	-$94K	–	1584
2025 Q1	$94K	Buy	+19,347	New	+$160K	﹤0.01%	1347
2023 Q4	–	Sell	-10,946	Closed	-$37K	–	1603
2023 Q3	$37K	Buy	+10,946	New	+$60.7K	﹤0.01%	1619
2022 Q3	–	Sell	-33,549	Closed	-$1.04M	–	1977
2022 Q2	$1.04M	Buy	+33,549	New	+$1.15M	0.01%	1062
2022 Q1	–	Sell	-9,545	Closed	-$415K	–	2301
2021 Q4	$415K	Buy	+9,545	New	+$432K	﹤0.01%	1512
2019 Q4	–	Sell	-7,379	Closed	-$386K	–	1615
2019 Q3	$386K	Buy	+7,379	New	+$344K	0.01%	774

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ExodusPoint Capital Management's EBS Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 19,347 shares — an estimated $94K sold.

ExodusPoint Capital Management first reported a position in EBS in Q3 2019 and held it in 5 quarters. The position peaked at $1.04M in Q2 2022. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

ExodusPoint Capital Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 19,347 Emergent Biosolutions shares in Q2 2025, an estimated $94K.
ExodusPoint Capital Management first reported a position in Emergent Biosolutions in Q3 2019 and held it in 5 quarters.
ExodusPoint Capital Management's Emergent Biosolutions position peaked at $1.04M in Q2 2022.
161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.